Testing a new therapy for metastatic cancer
Official title: Phase I Clinical Testing of a First-in-Class Therapy against Metastatic Cancer
Funded at Transcode Therapeutics, INC. · NIH-11005913 · Data updated 2026-11-12
This study is testing a new treatment called MN-anti-miR10b that aims to help people with metastatic cancer by targeting and eliminating cancer cells, and it may be used alongside low-dose chemotherapy to help shrink tumors.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Transcode Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 4, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,011,207 |
| NIH project number | 1R44CA295173-01 |
| Project ID | NIH-11005913 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with metastatic cancer who have not responded to standard treatments.
✕Less likely to help
Patients with early-stage cancer or those whose cancer has not metastasized may not benefit from this research.
What this research studies
This research investigates a novel therapeutic agent designed to specifically target and eliminate metastatic cancer cells. The therapy, known as MN-anti-miR10b, utilizes a unique delivery system to inhibit a specific microRNA associated with cancer spread. Patients may receive this treatment in combination with low-dose chemotherapy, with the aim of achieving significant regression of metastases. The approach has shown promising results in preclinical models, suggesting potential effectiveness in humans.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that significantly reduces or eliminates metastatic cancer, improving survival rates for patients.
How similar studies have gone: Previous research has shown promising results with similar approaches targeting microRNAs in cancer therapy, indicating potential for success in this novel treatment.
Where this research is happening
-
Transcode Therapeutics, INC.
Boston, United States Active
Researchers
- Principal investigator: Medarova, Zdravka O — Transcode Therapeutics, INC.
- Study coordinator: Medarova, Zdravka O
Related research
Other NIH-funded projects on the same topics.
-
Whole-Body Redox Maps to Guide Prostate Cancer Therapy
A new research project will map redox states across the body to understand how prostate cancer and its spread respond to therapy.
-
Digital activity tracking to understand metastatic breast cancer care
A smartphone-based activity tracking study will help people with metastatic cancer better understand how daily movement relates to health and treatment outcomes.
-
Measuring how cancer patients and doctors talk to each other to improve treatment outcomes
This project uses machine learning to study how patient-provider conversations affect cancer patients’ use of oral therapies and their health results.
-
Symptoms and quality of life during immunotherapy for metastatic cancer
The team will track symptoms and day-to-day quality of life in people with metastatic cancer who are receiving immune checkpoint inhibitor treatments.
-
A New Treatment for Metastatic Cancer
This project is exploring a brand-new treatment designed to specifically target and remove metastatic cancer cells in people with advanced cancer.
-
How cancer cells release proteins that help tumors spread
This project is learning how tumor cells send out certain proteins that help cancer move to other parts of the body, with the goal of helping people with metastatic cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.